Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.1K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.1K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

1.0K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.0K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

467
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
467
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

576
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
576
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

3.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Precision Antiplatelet Therapy: The Promise and Complexity of Pharmacogenomic Antiplatelet Therapy.

Circulation. Cardiovascular interventions·2026
Same author

Diabetes and cancer: therapeutic implications.

Cardio-oncology (London, England)·2026
Same author

Measuring Adherence to Multiple Medications Using Guideline-Directed Medical Therapy as a Model.

medRxiv : the preprint server for health sciences·2025
Same author

Assessing Medical Therapy Optimization in Cardiovascular-Kidney-Metabolic Clinical Trials: An Initiative From the Heart Failure Collaboratory.

JACC. Heart failure·2025
Same author

Platelet reactivity expression score in diabetes mellitus.

Blood vessels, thrombosis & hemostasis·2025
Same author

Accuracy of Electronic Health Record-Based Definitions for Patients with Heart Failure.

The American journal of medicine·2025

Related Experiment Video

Updated: Feb 25, 2026

Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology
10:41

Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology

Published on: January 23, 2021

8.5K

Cancer and Heart Failure: Understanding the Intersection.

Carine E Hamo1, Michelle W Bloom1

  • 1Department of Medicine, Stony Brook University Hospital, Stony Brook, New York, US.

Cardiac Failure Review
|August 9, 2017
PubMed
Summary

Cancer therapies can harm the heart, increasing risks for patients, especially those with existing heart conditions. A multidisciplinary cardio-oncology approach improves outcomes through early detection and management of treatment-related cardiac issues.

Keywords:
Heart failurebiomarkerscancercardiotoxicityimagingsurveillance

More Related Videos

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

12.3K

Related Experiment Videos

Last Updated: Feb 25, 2026

Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology
10:41

Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology

Published on: January 23, 2021

8.5K
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

12.3K

Area of Science:

  • Cardio-oncology
  • Cardiovascular disease
  • Cancer therapy

Background:

  • Cancer and cardiovascular disease are leading causes of death in the US.
  • Cancer therapies frequently cause cardiac toxicity.
  • Patients with pre-existing heart conditions face higher risks from cancer treatment.

Purpose of the Study:

  • To highlight the risks of cancer therapy on cardiac health.
  • To emphasize the potential for heart failure due to cancer treatment.
  • To advocate for a multidisciplinary cardio-oncology approach.

Main Methods:

  • Review of existing literature on cancer therapy-induced cardiotoxicity.
  • Analysis of patient outcomes in relation to cardiac comorbidities.
  • Discussion of surveillance, prevention, and treatment strategies.

Main Results:

  • Cancer treatments can lead to significant cardiac toxicity, including heart failure.
  • Cardiac complications may necessitate treatment disruption, impacting cancer survival.
  • Cardiovascular mortality can be increased by cancer treatment side effects.

Conclusions:

  • A multidisciplinary cardio-oncology approach is crucial for managing cardiac risks.
  • Early surveillance and intervention can mitigate adverse cardiac events.
  • Proactive management improves patient outcomes in cancer care.